Centre for Drug Design & Discovery (CD3)
Founded 2006
About Centre for Drug Design & Discovery (CD3)
The Centre for Drug Design and Discovery (CD3) is an investment fund and technology transfer platform aimed at promoting the discovery and development of innovative medicines for all kinds of diseases. CD3 achieves this goal by building further on the enormous pool of basic knowledge, innovation and technology of universities and spin-off companies. By providing the necessary expertise and financial resources, CD3 ensures that fundamental biomedical research carried out by universities and small biotech companies is translated into more usable results and promising molecules for new medicines. These new, potential medicines can then be further developed by pharmaceutical companies or form the basis for new spin-off companies. With this work method and philosophy, CD3 bridges the gap between academic innovative research and the pharmaceutical industry.
Company Facts
- Founded: 2006
- Operating status: Operating
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Website: cd3.eu
- Phone: (321)632-6484
Social Profiles
Canonical: https://fsome.com/organization/centre-for-drug-design-discovery-cd3-8451008 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.